The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293- 332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.
该发明涉及从LDL-R的
EGF(A)结构域衍生的化合物,特别是包括野生型
EGF(A)(LDL-R(293-332))序列的肽类类似物和至少一个含有至少一个
脂肪酸基团的取代基的化合物。该发明还涉及其制药组合物和药物的使用。该发明的新型
EGF(A)化合物可用于治疗,例如在降低
胆固醇、脂质代谢异常和心血管疾病领域。